Patents by Inventor Sean Ekins

Sean Ekins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists
    Publication number: 20020052693
    Abstract: The present invention relates to novel screening methods which enable the selection of neurokinin-1 (NK-1) receptor antagonist compounds which do not possess significant inhibitory potency towards cytochrome P450 enzymes, in particular, CYP2D6. The present invention also relates to a method of generating a pharmacophore model for the CYP2D6 inhibitory activity of NK-1 receptor antagonist compounds; to methods for the discovery of molecules that are potential NK-1 receptor antagonist compounds which do not possess significant inhibitory potency towards the CYP2D6 enzyme; to methods of modeling the features of the CYP2D6 pharmacophore useful in selecting NK-1 receptor antagonist molecules which do not possess significant potency towards CYP2D6.
    Type: Application
    Filed: January 17, 2001
    Publication date: May 2, 2002
    Inventors: Sean Ekins, Bill J. Smith
  • Single point interaction screen to predict IC50
    Publication number: 20020016681
    Abstract: This invention provides an improved computationally derived regression-based method for determining IC50 or EC50 values for chemical compounds, which predicts potential drug-drug interactions involving cytochrome P450 and other enzymes, transporters, receptors or proteins with active site(s). In addition, this approach predicts affinity for target enzymes, transporters and receptor proteins from a single compound concentration, which will rapidly enable identification of therapeutic use.
    Type: Application
    Filed: March 22, 2001
    Publication date: February 7, 2002
    Inventors: Sean Ekins, Feng Gao, Diane L. Johnson, Kevin G. Kelly, Ralph D. Meyer
  • Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
    Publication number: 20020013372
    Abstract: The present invention relates to novel screening methods which enable the selection of selective serotonin reuptake inhibitor (SSRI) compounds which do not possess significant inhibitory potency towards cytochrome P450 enzymes, in particular, CYP2D6. The present invention also relates to a method of generating a pharmacophore model for the CYP2D6 inhibitory activity of SSRI compounds; to methods for the discovery of molecules that are potential SSRI compounds which do not possess significant inhibitory potency towards the CYP2D6 enzyme; to methods of modeling the features of the CYP2D6 pharmacophore useful in selecting SSRI's which do not possess significant potency towards CYP2D6.
    Type: Application
    Filed: March 12, 2001
    Publication date: January 31, 2002
    Inventor: Sean Ekins
  • Method and device for drug-drug interaction testing sample preparation
    Publication number: 20010049092
    Abstract: A method and device for the automated large scale preparation for testing of drug-drug interactions, particularly with determination of IC50 and Ki, as a screening tool enhancement for determining viability of large numbers of compounds as drug candidates. Small samples of specific probe substrates and new compound inhibitors are automatically dispensed en masse into multi-welled reaction plates which are prefilled with thawed human microsomes, buffer and cofactor. The reaction plates are incubated and the reaction products are tested within degradation time limits, for initial biological determinations of relevant interaction effects of the compounds.
    Type: Application
    Filed: May 16, 2001
    Publication date: December 6, 2001
    Applicant: Pfizer Inc.
    Inventors: Sean Ekins, Diane Lynn Johnson, Kevin George Kelly